A. te Velde

发表

Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations.

N. Aaronson, M. Sprangers, M. Muller, 1998, Journal of clinical epidemiology.

Age of Diagnosis, Fidelity and Acceptability of an Early Diagnosis Clinic for Cerebral Palsy: A Single Site Implementation Study

A. te Velde, N. Badawi, E. Tantsis, 2021, Brain sciences.

Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.

L. Gras, A. te Velde, L. Boersma, 1998, International journal of radiation oncology, biology, physics.

Feasibility, psychometric performance, and stability across modes of administration of the CARES-SF.

N. Aaronson, M. Sprangers, A. te Velde, 1996, Annals of Oncology.

A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).

A. te Velde, J. Verweij, J. Smyth, 1996, Annals of Oncology.

The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life.

N. Aaronson, M. Sprangers, A. te Velde, 1999, European journal of cancer.

The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.

N. Aaronson, M. Groenvold, M. Sprangers, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.

A. te Velde, J. Verweij, L. Dirix, 1996, European journal of cancer.

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

A. te Velde, S. Aamdal, R. Paridaens, 1996, British Journal of Cancer.

Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.

S. Rodenhuis, O. Dalesio, A. te Velde, 1996, Anticancer research.

Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.

A. te Velde, J. Wanders, J. Verweij, 1996, British Journal of Cancer.

Adjustment of the interface detector (location 71) to the absolute number of mononuclear cells in the peripheral blood: No improvement of the collection efficiency of the Fenwal CS3000 plus during progenitor cell harvests

O. Dalesio, A. te Velde, C. E. van der Schoot, 1997, Journal of clinical apheresis.

Early Diagnosis and Classification of Cerebral Palsy: An Historical Perspective and Barriers to an Early Diagnosis

A. te Velde, N. Badawi, E. Tantsis, 2019, Journal of clinical medicine.

State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy

A. te Velde, N. Badawi, I. Novak, 2020, Current Neurology and Neuroscience Reports.

Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer

D. Osoba, B. Zee, N. Aaronson, 1997, Quality of Life Research.

[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation].

H. Bartelink, A. te Velde, W. Meinhardt, 1996, Nederlands tijdschrift voor geneeskunde.

Linking data from a large clinical trial with the Australian Cerebral Palsy Register

L. Doyle, A. te Velde, P. Middleton, 2020, Developmental medicine and child neurology.

Best practice guidelines for communicating to parents the diagnosis of disability.

A. te Velde, I. Novak, C. Morgan, 2019, Early human development.

Rehabilitation Evidence-Based Decision-Making: The READ Model

A. te Velde, I. Novak, C. Morgan, 2021, Frontiers in Rehabilitation Sciences.